Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1955 2
1957 1
1958 1
1959 4
1961 1
1962 3
1963 9
1964 4
1965 6
1966 8
1967 7
1968 2
1969 1
1970 2
1971 3
1972 4
1973 2
1974 1
1975 3
1976 1
1977 2
1978 2
1979 7
1980 8
1981 9
1982 13
1983 11
1984 21
1985 26
1986 28
1987 28
1988 26
1989 37
1990 32
1991 39
1992 55
1993 34
1994 39
1995 67
1996 72
1997 79
1998 74
1999 98
2000 113
2001 108
2002 160
2003 165
2004 208
2005 241
2006 265
2007 265
2008 379
2009 422
2010 463
2011 496
2012 513
2013 601
2014 699
2015 784
2016 800
2017 807
2018 1022
2019 1122
2020 1337
2021 1651
2022 1796
2023 1752
2024 1364

Text availability

Article attribute

Article type

Publication date

Search Results

16,557 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. Among authors: lu s. N Engl J Med. 2024 Jun 26. doi: 10.1056/NEJMoa2403614. Online ahead of print. N Engl J Med. 2024. PMID: 38924756
BCAA-producing Clostridium symbiosum promotes colorectal tumorigenesis through the modulation of host cholesterol metabolism.
Ren YM, Zhuang ZY, Xie YH, Yang PJ, Xia TX, Xie YL, Liu ZH, Kang ZR, Leng XX, Lu SY, Zhang L, Chen JX, Xu J, Zhao EH, Wang Z, Wang M, Cui Y, Tan J, Liu Q, Jiang WH, Xiong H, Hong J, Chen YX, Chen HY, Fang JY. Ren YM, et al. Among authors: lu sy. Cell Host Microbe. 2024 Aug 1:S1931-3128(24)00271-3. doi: 10.1016/j.chom.2024.07.012. Online ahead of print. Cell Host Microbe. 2024. PMID: 39106870
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection.
Peluso MJ, Ryder D, Flavell RR, Wang Y, Levi J, LaFranchi BH, Deveau TM, Buck AM, Munter SE, Asare KA, Aslam M, Koch W, Szabo G, Hoh R, Deswal M, Rodriguez AE, Buitrago M, Tai V, Shrestha U, Lu S, Goldberg SA, Dalhuisen T, Vasquez JJ, Durstenfeld MS, Hsue PY, Kelly JD, Kumar N, Martin JN, Gambhir A, Somsouk M, Seo Y, Deeks SG, Laszik ZG, VanBrocklin HF, Henrich TJ. Peluso MJ, et al. Among authors: lu s. Sci Transl Med. 2024 Jul 3;16(754):eadk3295. doi: 10.1126/scitranslmed.adk3295. Epub 2024 Jul 3. Sci Transl Med. 2024. PMID: 38959327 Free PMC article.
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, de la Mora Jimenez E, Zhou J, Pérol M, Lee KH, Vicente D, Ichihara E, Riely GJ, Luo Y, Chirovsky D, Pietanza MC, Bhagwati N, Lu S. Yang JC, et al. Among authors: lu s. J Clin Oncol. 2024 Aug 22:JCO2302747. doi: 10.1200/JCO.23.02747. Online ahead of print. J Clin Oncol. 2024. PMID: 39173098
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Camidge DR, et al. Among authors: lu s. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6. J Clin Oncol. 2024. PMID: 38843488 Free PMC article. Clinical Trial.
Mitochondrial metabolic reprogramming in diabetic kidney disease.
Fan X, Yang M, Lang Y, Lu S, Kong Z, Gao Y, Shen N, Zhang D, Lv Z. Fan X, et al. Among authors: lu s. Cell Death Dis. 2024 Jun 24;15(6):442. doi: 10.1038/s41419-024-06833-0. Cell Death Dis. 2024. PMID: 38910210 Free PMC article. Review.
16,557 results
You have reached the last available page of results. Please see the User Guide for more information.